Jonathan Braun

Dr. Jonathan Braun

orcid

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Cell
Verified
Journal Article
Closed access
LSLi Sun
Li Sun
YPYuanzhen Peng
Yuanzhen Peng
ASAllison C. Sharrow
Allison C. Sharrow
JIJameel Iqbal
Jameel Iqbal
ZZZhiyuan Zhang
Zhiyuan Zhang
MZMone Zaidi
Mone Zaidi

8 January 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
MSMelanie Schirmer
Melanie Schirmer
EFEric A. Franzosa
Eric A. Franzosa
JLJason Lloyd-Price
Jason Lloyd-Price
LMLauren J. McIver
Lauren J. McIver
RSRandall Schwager
Randall Schwager
CHCurtis Huttenhower
Curtis Huttenhower

1 January 2019 in Immunity
Verified
Journal Article
Closed access
GBGraham Britton
Graham Britton
ECEduardo J. Contijoch
Eduardo J. Contijoch
IMIlaria Mogno
Ilaria Mogno
OVOlivia H. Vennaro
Olivia H. Vennaro
SLSean R. Llewellyn
Sean R. Llewellyn
JFJeremiah J. Faith
Jeremiah J. Faith

1 April 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JEJoseph E. Ebinger
Joseph E. Ebinger
JFJustyna Fert-Bober
Justyna Fert-Bober
IPIgnat Printsev
Ignat Printsev
MWMin Wu
Min Wu
NSNancy Sun
Nancy Sun
Kimia SobhaniKimia Sobhani
Kimia Sobhani
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

1 March 2019 in Cell Host & Microbe
Verified
Journal Article
Closed access
JLJose J. Limon
Jose J. Limon
JTJie Tang
Jie Tang
DLDalin Li
Dalin Li
AWAndrea J. Wolf
Andrea J. Wolf
KMKathrin S. Michelsen
Kathrin S. Michelsen
DUDavid M. Underhill
David M. Underhill

1 January 1992 in Cytometry
Verified
Journal Article
Open access
PDF file
ISIngrid Schmid
Ingrid Schmid
WKWanda J. Krall
Wanda J. Krall
CUChristel H. Uittenbogaart
Christel H. Uittenbogaart
JBJonathan Braun
Jonathan Braun
JGJanis V. Giorgi
Janis V. Giorgi
Identification of nonviable cells in immunofluorescently stained cell populations is essential for obtaining accurate data. Fluorescent non‐vital DNA dyes, particularly propidium iodide (PI), have been used routinely in flow cytometry for discrimination of dead cells from viable cells on the basis of fluorescence. We describe here the use of an alternative DNA dye, 7‐amino‐actinomycin D (7‐AAD), which can replace PI for the exclusion of nonviable cells. As an example, we present in this paper the utilization of 7‐AAD on various leukemic cell lines for dead cell exclusion whenever the viable cell population could not be discriminated reliably from nonviable cells on the light scatter histogram; 7‐AAD is suitable for dead cell discrimination in lengthy experiments because it is efficiently excluded by intact cells and has a high DNA binding constant. In addition, the dye is valuable in combination with phycoerythrin (PE)‐fluorescence dual‐color flow cytometry on a single argon laser instrument, since its emission in the far red can easily be separated from the emission of PE; 7‐AAD was used on fluoresceinisothiocyanate (FITC) and PE surface‐labeled human thymocytes for characterization of the dying subpopulation of cells which is undergoing programmed cell death. In this heterogeneous cell preparation, the spectral properties of the dye permitted the classification of viable and nonviable cell subpopulations by multiparameter analysis.